Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in ...

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...

“Pairing strategic changes to your diet along with exercise can help boost your calorie burn slightly and help maintain a ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

Monlunabant shows significant and clinically meaningful weight loss over 16 weeks in patients with obesity and metabolic ...

Michigan’s new bipartisan state budget will limit Medicaid coverage of a group of weight loss drugs whose use has exploded in popularity in recent years.

Midlife weight gain is a persistent challenge for many women, but emerging research suggests hormone therapy may enhance response to glucagon-like peptide-1 (GLP-1)–based treatments.

Insurance denials and high prices leave patients with obesity looking for other options. With millions of Americans using ...

Anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much weight people lose while taking the drug, according to a new study led by a ...

Development of the latest class of incretin-based therapeutics for diabetes and obesity has been heralded as a major step ...